Celcuity

About:

Celcuity is a biotechnology company translating discoveries of new cancer sub-types into expanded therapeutic options for cancer patients.

Website: http://celcuity.com

Top Investors: Blue Owl, New Enterprise Associates, RA Capital Management, Soleus Capital, Venrock Healthcare Capital Partners

Description:

Celcuity is a clinical-stage biotechnology company translating discoveries of new cancer sub-types into pioneering companion diagnostics and expanded therapeutic options for cancer patients. Celcuity's 3rd generation diagnostic platform, CELsignia, analyzes living tumor cells to untangle the complexity of the cellular activity driving a patient's cancer. This allows Celcuity to discover new cancer sub-types molecular diagnostics cannot detect. Celcuity is driven to improve outcomes for patients and to transform how pharmaceutical companies define the patient populations for their targeted therapies.

Total Funding Amount:

$336M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Hamel, Minnesota, United States

Founded Date:

2012-01-01

Founders:

Brian Sullivan, Lance Laing

Number of Employees:

11-50

Last Funding Date:

2024-05-30

IPO Status:

Public

© 2025 bioDAO.ai